再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

已收盘 04-22 16:08:12

24.400

+1.600

+7.02%

最高24.850	最低23.200	成交量1,301万
今开23.300	昨收22.800	日振幅7.24%
总市值268.64亿	流通市值268.64亿	总股本11.01亿
成交额3.16亿	换手率1.18%	流通股本11.01亿
市净率4.12	ROE-31.41%	每股收益-2.02
52周最高32.500	52周最低10.560	市盈率-12.10
股息0.00	股息收益率0.00	ROA-15.87%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":24.4,"timestamp":1745309292021,"preClose":22.8,"halted":0,"volume":13014072,"delay":0,"floatShares":1101000000,"shares":1101000000,"eps":-2.0157560336066656,"marketStatus":"已收盘","change":1.6,"latestTime":"04-22 16:08:12","open":23.3,"high":24.85,"low":23.2,"amount":316261381,"amplitude":0.072368,"askPrice":24.45,"askSize":148900,"bidPrice":24.4,"bidSize":4300,"shortable":3,"etf":0,"ttmEps":-2.0157560336066656,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745371800000},"marketStatusCode":5,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":22.8,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"volumeRatio":0.935761,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"2529943371","title":"再鼎医药(ZLAB)盘前涨超7% 瑞普替尼新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529943371","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529943371?lang=zh_cn&edition=full","pubTime":"2025-04-22 18:52","pubTimestamp":1745319158,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药(ZLAB)盘前涨超7%，截至发稿，报31.87美元。消息面上，4月21日，再鼎医药宣布，国家药品监督管理局（NMPA）已受理瑞普替尼（repotrectinib）的补充新药上市申请（sNDA），用于治疗携带神经营养酪氨酸受体激酶（NTRK）基因融合的实体瘤成人患者，该类患者为局部晚期、转移性，或手术切除可能导致严重并发症的患者，且这些患者在接受既往治疗后出现疾病进展，或缺乏有效的治疗方案选择。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/OWU4OGExOTI2NzgyMTc2NjE0.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OWU4OGExOTI2NzgyMTc2NjE0.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"287723","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4139","BK4588","BK4585","09688","BK4526","ZLAB","BK1574","BK4548","LU2488822045.USD","BK1588","BK4531"],"gpt_icon":0},{"id":"2529321023","title":"再鼎医药04月22日主力净流入1772万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529321023","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529321023?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:16","pubTimestamp":1745309799,"startTime":"0","endTime":"0","summary":"04月22日, 再鼎医药股价涨7.02%，报收24.40元，成交金额3.16亿元，换手率1.18%，振幅7.24%，量比0.93。再鼎医药今日主力资金净流入1772万元，上一交易日主力净流出205万元。该股近5个交易日上涨8.78%，主力资金累计净流入3686万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入3.03亿元，其中净流入天数为15日。该股主力净额占比0.07%，港股市场排名108/2647。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171344a4623b90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171344a4623b90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09688","BK1588","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2529345581","title":"港股异动 | 再鼎医药(09688)涨超7% 瑞普替尼新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529345581","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529345581?lang=zh_cn&edition=full","pubTime":"2025-04-22 15:34","pubTimestamp":1745307273,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超7%，截至发稿，涨7.02%，报24.4港元，成交额2.79亿港元。另外，公司合作伙伴argenx近日宣布，艾加莫德预充针皮下注射剂型获美国FDA批准上市。据悉，目前在国内，艾加莫德已有静脉输注和皮下注射2种给药方式。再鼎医药将于2025年在国内递交艾加莫德预充式皮下注射剂型的上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4139","BK4588","BK4585","ZLAB","BK4548","BK1161","BK4526","BK1588","09688","LU2488822045.USD","BK4531"],"gpt_icon":0},{"id":"2529391901","title":"港股医药逆势走强 港股医药ETF涨超3% 冲击四连涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2529391901","media":"东方财富证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529391901?lang=zh_cn&edition=full","pubTime":"2025-04-22 11:10","pubTimestamp":1745291400,"startTime":"0","endTime":"0","summary":"4月22日，港股市场集体震荡环境下，港股医药带头领涨，港股医药ETF上涨3.10%，冲击4连涨。成分股石药集团、百济神州、信达生物、再鼎医药、康方生物上涨超 5%。港股医药ETF紧密跟踪中证港股通医药卫生综合指数，中证港股通医药卫生综合指数从港股通范围内选取50只流动性较好、市值较大的医疗卫生行业上市公司证券作为指数样本，以反映港股通范围内医药卫生上市公司证券的整体表现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422111145a6c32f7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422111145a6c32f7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999004220.SGD","LU1226287529.USD","LU1152091168.USD","LU0880133367.SGD","LU1960683339.HKD","LU0501845795.SGD","LU0140636845.USD","LU1152091754.HKD","IE00BZ08YS42.EUR","HSTECH","LU1226287875.USD","06160","LU0067412154.USD","LU0072913022.USD","LU1226288253.USD","09688","IE0008369823.USD","LU1993786604.SGD","LU1226288170.HKD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","01093","LU1008478684.HKD","IE00B5MMRT66.SGD","LU0326950275.SGD","09926","LU1951186391.HKD","IE0008368742.USD","01801","IE00B543WZ88.USD","LU1226287792.SGD","BK1521","BK1191","LU1807302812.USD","BK1515","IE00B031HY20.USD"],"gpt_icon":1},{"id":"1167239425","title":"异动解读 | 再鼎医药盘中大涨7.46%，南向资金持续加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=1167239425","media":"异动解读","labels":["movement"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167239425?lang=zh_cn&edition=full","pubTime":"2025-04-22 10:12","pubTimestamp":1745287947,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大涨7.46%，引发市场关注。分析人士认为，这一涨幅可能与南向资金持续加仓有关。截至当日收盘，港股通共持有再鼎医药1.99亿股，占流通股18.10%。值得注意的是，再鼎医药近5个交易日上涨4.59%，期间港股通累计增持2105.94万股；虽然近20个交易日下跌23.62%，但港股通仍累计增持4455.90万股，显示出南向资金对该股的持续看好。然而，投资者仍需警惕市场风险，密切关注公司基本面变化和行业动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 再鼎医药盘中大涨7.46%，南向资金持续加仓","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09688"],"gpt_icon":0},{"id":"2528892760","title":"再鼎医药04月17日遭主力抛售205万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528892760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528892760?lang=zh_cn&edition=full","pubTime":"2025-04-17 16:15","pubTimestamp":1744877758,"startTime":"0","endTime":"0","summary":"04月17日, 再鼎医药股价跌1.30%，报收22.80元，成交金额2.34亿元，换手率0.93%，振幅5.19%，量比0.66。再鼎医药今日主力资金净流出205万元，上一交易日主力净流出1291万元。该股近5个交易日上涨5.73%，主力资金累计净流入1.48亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2.87亿元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417170254a45c4321&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417170254a45c4321&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","09688","BK1588","BK1574"],"gpt_icon":0},{"id":"2528781917","title":"中金：维持再鼎医药(09688)跑赢行业评级 目标价34.41港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528781917","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528781917?lang=zh_cn&edition=full","pubTime":"2025-04-17 09:15","pubTimestamp":1744852527,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持再鼎医药2025年和2026年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持H/US股目标价34.41港元/44.24美元不变。4月11日，公司合作伙伴argenx宣布艾加莫德预充针皮下注射剂型获美国FDA批准上市。目前在国内，艾加莫德已有静脉输注和皮下注射2种给药方式，公司将于2025年在国内递交艾加莫德预充式皮下注射剂型的上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ZLAB","09688"],"gpt_icon":1},{"id":"2527970172","title":"高盛研报：重症肌无力市场格局重塑？强烈看好再鼎医药艾加莫德绝对竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2527970172","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527970172?lang=zh_cn&edition=full","pubTime":"2025-04-16 18:53","pubTimestamp":1744800794,"startTime":"0","endTime":"0","summary":"艾加莫德的快速起效特性，使其在急性和难治性患者中尤为受欢迎。这可能成为未来竞争格局中推动艾加莫德市场份额扩大的重要因素。这表明艾加莫德可以作为一种可靠的维持治疗方案。“研究外”要素不容忽视高盛的报告指出，随着重症肌无力药物选择的愈加丰富，除了临床数据外，还有诸多“临床研究外”因素可能影响竞争格局。高盛认为，这一时间差为艾加莫德提供了至少两年的市场先发优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504161857109739d59c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504161857109739d59c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","09688","LU2488822045.USD","BK1574","BK1161"],"gpt_icon":0},{"id":"2527298983","title":"再鼎医药04月16日主力净流出1291万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527298983","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527298983?lang=zh_cn&edition=full","pubTime":"2025-04-16 16:15","pubTimestamp":1744791321,"startTime":"0","endTime":"0","summary":"04月16日, 再鼎医药股价跌4.55%，报收23.10元，成交金额2.61亿元，换手率1.03%，振幅6.61%，量比0.73。再鼎医药今日主力资金净流出1291万元，上一交易日主力净流入834万元。该股近5个交易日上涨3.10%，主力资金累计净流入1.81亿元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入2.93亿元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416173240a6bc6331&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416173240a6bc6331&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1574","BK1161","BK1588","LU2488822045.USD"],"gpt_icon":0},{"id":"2527839932","title":"再鼎医药盘中异动 早盘股价大跌5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527839932","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527839932?lang=zh_cn&edition=full","pubTime":"2025-04-16 10:19","pubTimestamp":1744769965,"startTime":"0","endTime":"0","summary":"2025年04月16日早盘10时19分，再鼎医药股票出现异动，股价急速跳水5.17%。截至发稿，该股报22.950港元/股，成交量317.596万股，换手率0.29%，振幅3.51%。再鼎医药股票所在的生物技术行业中，整体跌幅为2.30%。其相关个股中，复宏汉霖、贝康医疗-B、荃信生物-B涨幅较大，振幅较大的相关个股有歌礼制药-B、科伦博泰生物-B、荣昌生物，振幅分别为9.44%、7.99%、7.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041610192597394a6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041610192597394a6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","09688","LU2488822045.USD","BK1574","BK1161"],"gpt_icon":0},{"id":"1126441949","title":"异动解读 | 再鼎医药盘中大涨5.34%，南向资金持续加仓或成推手","url":"https://stock-news.laohu8.com/highlight/detail?id=1126441949","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126441949?lang=zh_cn&edition=full","pubTime":"2025-04-15 10:10","pubTimestamp":1744683030,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大涨5.34%，引发市场关注。这一涨势很可能与南向资金的持续加仓有关。截至当日收盘，港股通共持有再鼎医药1.8685亿股，占流通股的16.97%。值得注意的是，再鼎医药近5个交易日已上涨12.73%，同期港股通累计增持1678.81万股，显示出投资者对该股的持续看好。南向资金的增持往往被视为看好公司前景的信号，可能吸引更多投资者跟随买入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09688"],"gpt_icon":0},{"id":"1149995493","title":"异动解读 | 再鼎医药盘中大涨5.34%，南向资金大幅增持","url":"https://stock-news.laohu8.com/highlight/detail?id=1149995493","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149995493?lang=zh_cn&edition=full","pubTime":"2025-04-15 10:10","pubTimestamp":1744683029,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大涨5.34%，引起市场广泛关注。该股在早盘交易中表现突出，成为港股市场中的亮点之一。据悉，在4月14日，南向资金大幅增持再鼎医药474.18万股。截至当日收盘，港股通共持有再鼎医药1.8685亿股，占公司流通股的16.97%。数据显示，该股在近5个交易日内累计上涨12.73%，期间港股通累计增持1678.81万股。然而，从更长期来看，再鼎医药在近20个交易日内下跌16.61%，但港股通仍然选择逆势增持，累计增持量达到3305.81万股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09688"],"gpt_icon":0},{"id":"2527768191","title":"美股异动 | 再鼎医药(ZLAB.US)涨逾8% FDA批准艾加莫德预充式皮下注射剂型","url":"https://stock-news.laohu8.com/highlight/detail?id=2527768191","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527768191?lang=zh_cn&edition=full","pubTime":"2025-04-14 22:59","pubTimestamp":1744642769,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，再鼎医药(ZLAB.US)盘中一度涨超13%，截至发稿，涨逾8%，报32.09美元。消息面上，4月11日，再鼎医药合作伙伴argenx公司宣布，美国食品药品监督管理局(FDA)已正式批准了艾加莫德预充式皮下注射剂型，用于治疗乙酰胆碱受体(AChR)抗体阳性的全身型重症肌无力(gMG)成人患者和慢性炎性脱髓鞘性多发性神经根神经病(CIDP)成人患者。再鼎医药表示，将于2025年在国内递交艾加莫德预充式皮下注射剂型的上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"美股异动 | 再鼎医药(ZLAB.US)涨逾8% FDA批准艾加莫德预充式皮下注射剂型","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4548","ZLAB","BK4526","09688","BK4139","BK1574","BK1161","BK1588","BK4585","BK4531","LU2488822045.USD"],"gpt_icon":0},{"id":"2527188984","title":"再鼎医药盘前续涨超6% 将于今年递交艾加莫德预充式皮下注射剂型上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2527188984","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527188984?lang=zh_cn&edition=full","pubTime":"2025-04-14 16:22","pubTimestamp":1744618954,"startTime":"0","endTime":"0","summary":"再鼎医药(ZLAB.US)盘前续涨超6%，报31.32美元。该股上周五大幅收涨超21.4%。消息面上，4月11日，再鼎医药合作伙伴argenx公司宣布，美国食品药品监督管理局(FDA)已正式批准了艾加莫德预充式皮下注射剂型，用于治疗乙酰胆碱受体(AChR)抗体阳性的全身型重症肌无力(gMG)成人患者和慢性炎性脱髓鞘性多发性神经根神经病(CIDP)成人患者。再鼎医药表示，将于2025年在国内递交艾加莫德预充式皮下注射剂型的上市申请。\n\n\r\n            责任编辑：小讯","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2025/04/14162249519024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4139","09688","BK1161","BK1574","BK4588","BK4526","BK4531","BK4548","ZLAB","BK4585","BK1588","LU2488822045.USD"],"gpt_icon":0},{"id":"2527921945","title":"【券商聚焦】德邦证券：再鼎医药艾加莫德优势明显，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2527921945","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527921945?lang=zh_cn&edition=full","pubTime":"2025-04-14 11:31","pubTimestamp":1744601489,"startTime":"0","endTime":"0","summary":"艾加莫德作为全球首款FcRn拮抗剂，其快速起效和长期有效性、安全性优异的特点在临床试验中得到了充分验证。尽管存在临床研发失败、竞争格局恶化和行业政策风险，但艾加莫德的优势明显，有望成为新一代自免大单品，因此维持“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957142","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","ZLAB","09688"],"gpt_icon":0},{"id":"2527949291","title":"港股异动 | 医药股涨幅居前 再鼎医药(09688)涨近15% 和铂医药-B(02142)涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527949291","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527949291?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:57","pubTimestamp":1744595830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，医药股早盘涨幅居前，截至发稿，再鼎医药涨14.86%，报25.5港元；和铂医药-B涨10.07%，报7.87港元；荣昌生物涨8.22%，报30.95港元；君实生物涨8.1%，报15.22港元；来凯医药-B涨7.71%，报11.46港元。此外，财报层面：头部港股创新药公司受益于License-out放量，营收和利润稳步增长。该行表示，年初以来在DeepSeek的激励下，港股市场交投情形改善显著，相比之下，港股医药板块的关注度并不算高，对医药的基本面修复，市场定价或尚不充分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1277939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","01877","LU1969619763.USD","BK4548","BK1574","09939","BK4531","BK1161","09688","LU2328871848.SGD","BK1583","BK4588","ZLAB","LU2488822045.USD","BK4139","09995","BK1588","02142","BK1515","159938","BK4526","02105"],"gpt_icon":0},{"id":"2527945141","title":"港股生物医药板块盘初走强，再鼎医药涨超12%，君实生物涨超5%，百济神州、药明康德等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527945141","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527945141?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:44","pubTimestamp":1744595082,"startTime":"0","endTime":"0","summary":"港股生物医药板块盘初走强，再鼎医药涨超12%，君实生物涨超5%，百济神州、药明康德等跟涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/14094449514121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["399441","BK1576","06160","BK4585","LU0052750758.USD","688180","BK4531","BK1161","BK4548","BK4139","ONC","LU2045819591.USD","BK1500","BK1141","BK1583","688235","01877","BK1515","LU2242644610.SGD","HSTECH","BK0216","02359","LU2125910500.SGD","BK1574","LU0307460666.USD","BK1588","LU2488822045.USD","LU0320764599.SGD","BK4614","LU0708995583.HKD","ZLAB","BK0239","LU1969619763.USD","09688","BK4526","LU0456842615.SGD","LU1997245094.SGD","LU2328871848.SGD","603259","161726","LU1997245177.USD","YANG","LU0588546209.SGD","LU1046422090.SGD","BK4588"],"gpt_icon":0},{"id":"2527945619","title":"港股生物医药板块盘初走强，再鼎医药(09688.HK)涨超12%，君实生物(01877.HK)涨超5%，百济神州(061","url":"https://stock-news.laohu8.com/highlight/detail?id=2527945619","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527945619?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:43","pubTimestamp":1744595016,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2125910500.SGD","LU1997245094.SGD","LU1046422090.SGD","LU2242644610.SGD","LU0320764599.SGD","02359","BK4614","BK4585","688235","LU0456842615.SGD","HSCEI","01877","BK4548","LU1969619763.USD","BK1574","BK1500","LU1997245177.USD","HSTECH","BK1141","161726","BK4531","LU0307460666.USD","ONC","BK0239","09688","BK1161","LU2045819591.USD","LU0588546209.SGD","LU2328871848.SGD","BK1583","06160","BK4588","ZLAB","LU2488822045.USD","688180","LU0052750758.USD","07226","BK4139","BK1588","399441","603259","BK1515","YANG","BK0216","BK4526","LU0708995583.HKD","BK1576"],"gpt_icon":0},{"id":"2527945435","title":"【港股医药股多数走强 再鼎医药涨超13%】截至发稿，再鼎医药(09688.HK)涨13.51%、来凯医药-B(02105.HK)涨10.34%、基石药业-B(02616.HK)涨6.28%、腾盛博药-B(02137.HK)涨6.17%、药明合联(02268.HK)涨5.94%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527945435","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527945435?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:42","pubTimestamp":1744594975,"startTime":"0","endTime":"0","summary":"截至发稿，再鼎医药(09688.HK)涨13.51%、来凯医药-B(02105.HK)涨10.34%、基石药业-B(02616.HK)涨6.28%、腾盛博药-B(02137.HK)涨6.17%、药明合联(02268.HK)涨5.94%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/14094249513998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02137","BK4531","02268","BK1588","BK4526","02105","BK4548","BK4139","BK1141","09688","BK1574","BK4585","BK4588","SG9999014674.SGD","LU2488822045.USD","ZLAB","159718","BK1587","BK1161","02616"],"gpt_icon":0},{"id":"1193399009","title":"港股生物医药股大幅上涨，永泰生物-B涨超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193399009","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193399009?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:40","pubTimestamp":1744594831,"startTime":"0","endTime":"0","summary":"4月14日，港股生物医药股大幅上涨，$永泰生物-B(06978)$涨超15%，$再鼎医药(09688)$涨超13%，$荣昌生物(09995)$、$和铂医药-B(02142)$、$腾盛博药-B(02137)$涨超6%.","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YANG","BK1161","BK4139","BK4531","ZLAB","BK1574","09995","BK4588","09688","BK4585","BK4614","07226","HSCEI","06978","LU2328871848.SGD","02137","BK1583","HSTECH","02142","LU2488822045.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0459},{"period":"1month","weight":-0.2375},{"period":"3month","weight":0.1176},{"period":"6month","weight":0.0459},{"period":"1year","weight":1.0357},{"period":"ytd","weight":0.0909}],"compareEarnings":[{"period":"1week","weight":0.0345},{"period":"1month","weight":-0.1352},{"period":"3month","weight":0.0925},{"period":"6month","weight":0.0284},{"period":"1year","weight":0.3165},{"period":"ytd","weight":0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.013207},{"month":2,"riseRate":0.6,"avgChangeRate":0.053227},{"month":3,"riseRate":0.2,"avgChangeRate":-0.100669},{"month":4,"riseRate":0.6,"avgChangeRate":0.020883},{"month":5,"riseRate":0.5,"avgChangeRate":-0.025575},{"month":6,"riseRate":0.25,"avgChangeRate":-0.052584},{"month":7,"riseRate":0.75,"avgChangeRate":0.064885},{"month":8,"riseRate":0.75,"avgChangeRate":0.004625},{"month":9,"riseRate":0.25,"avgChangeRate":-0.078066},{"month":10,"riseRate":0.6,"avgChangeRate":-0.01228},{"month":11,"riseRate":0.6,"avgChangeRate":0.099288},{"month":12,"riseRate":0.4,"avgChangeRate":-0.001944}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}